AACR-KCA 2024, Seoul x KACTUS
We’re excited to announce our participation in the AACR-KCA Joint Conference on Precision Medicine in Cancer, happening in Seoul, Korea, from November 21st to 22nd, 2024. This prestigious event will bring together leading oncology experts to discuss the latest advancements in cancer research.
There’s still time to submit your abstracts- deadline is September 25th, 2024. Early registration is open until October 15th, 2024, offering discounted rates. Don’t miss this opportunity to engage in this premier oncology event.
What is AACR-KCA?
The AACR-KCA Joint Conference is a collaboration between the American Association for Cancer Research (AACR) and the Korean Cancer Association (KCA). This conference focuses on advancements in cancer research and precision medicine, offering a platform for experts to discuss the latest scientific discoveries, clinical applications, and emerging technologies in oncology.
Event Overview
Venue: Lotte Hotel Seoul, 30 Eulji-ro, Jung District, Seoul, South Korea
Dates: November 21st to 22nd, 2024
- Conference Day 1: Thursday 21 November, 2024 8:20am - 5:30pm
- Conference Day 2: Friday 22 November, 2024 8:00am - 5:30pm
Event Schedule
The two-day AACR-KCA Joint Conference will feature a robust program with diverse speakers and topics. For full details, refer to the AACR-KCA Scientific Program.
Day 1 November 21st 2024
- Opening Remarks at 8:20am
- Poster Display from 8:30am to 12:00pm and from 12:30pm to 5:30pm
- Educational Session from 8:30am to 10:10am
- Targeting RAS in Cancer
- Keynote Lecture from 10:30am to 11:10am
- Luncheon Symposia from 11:20am to 12:00pm
- Poster Session 1 from 12:00pm to 12:30pm
- Plenary Session 1 from 12:30pm to 2:10pm
- Patient Derived Models
- Plenary Session 2 from 2:30pm to 4:10pm
- Tumor Heterogeneity
- Proffered Paper Sessions 1 and 2 from 4:30pm to 5:30pm
Day 2 November 22nd 2024
- Educational Session 2 from 8:00am to 9:30am
- Cancer Neuroscience
- Poster Display from 8:00am to 1:10pm and from 1:40pm to 5:20pm
- Plenary Session 3 from 9:40am to 11:20am
- EBV Related Cancers
- Waun Ki Hong Memorial Lecture from 11:40am to 12:20pm
- Luncheon Symposia from 12:30pm to 1:10pm
- Poster Session 1 from 1:10pm to 1:40pm
- Plenary Session 4 from 1:40pm to 3:20pm
- AI in Cancer Research and Treatment
- Plenary Session 5 from 3:40pm to 5:20pm
- Advances in Immuno-oncology
- Awards Ceremony starting at 5:20pm
About KACTUS
KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our expansive catalog, boasting over 2500 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of our product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.
Featured Products
Explore more
Popular posts
